Roivant Sciences Ltd. Segments Disclosure
| Years Ended March 31, | |||||||||||||||||
| 2026 | 2025 | 2024 | |||||||||||||||
| Revenue | $ | 8,260 | $ | 29,053 | $ | 32,713 | |||||||||||
| Less: | |||||||||||||||||
| Cost of revenues | 1,285 | 911 | 1,599 | ||||||||||||||
| Program-specific research and development expenses: | |||||||||||||||||
| Anti-FcRn franchise—endocrine diseases | 90,359 | 63,073 | 33,205 | ||||||||||||||
| Anti-FcRn franchise—neurological diseases | 82,515 | 93,224 | 41,060 | ||||||||||||||
| Anti-FcRn franchise—rheumatology diseases | 48,813 | 23,897 | — | ||||||||||||||
| Anti-FcRn franchise—dermatology diseases | 20,264 | 15,633 | — | ||||||||||||||
| Anti-FcRn franchise—other clinical and nonclinical | 3,367 | 9,327 | 39,811 | ||||||||||||||
| Anti-FcRn franchise—contractual costs related to batoclimab program discontinuation | 38,952 | — | — | ||||||||||||||
| Brepocitinib | 60,272 | 45,125 | 38,563 | ||||||||||||||
| Mosliciguat | 36,077 | 19,746 | 4,307 | ||||||||||||||
| Other development and discovery programs | 48,251 | 57,729 | 92,270 | ||||||||||||||
| Research and development share-based compensation | 47,867 | 39,780 | 32,400 | ||||||||||||||
| Research and development personnel-related expenses | 167,790 | 146,162 | 123,283 | ||||||||||||||
| Other research and development expenses | 37,285 | 36,717 | 35,010 | ||||||||||||||
| Acquired in-process research and development | — | — | 26,450 | ||||||||||||||
| General and administrative share-based compensation | 298,298 | 239,505 | 154,873 | ||||||||||||||
| General and administrative personnel-related expenses | 135,850 | 205,737 | 126,163 | ||||||||||||||
| Other general and administrative expenses | 176,318 | 146,168 | 135,097 | ||||||||||||||
| Gain on sale of Telavant net assets | — | (110,387) | (5,348,410) | ||||||||||||||
| Gain on litigation settlement | (770,235) | — | — | ||||||||||||||
| Change in fair value of investments | (105,046) | (55,186) | 47,973 | ||||||||||||||
| Change in fair value of liability instruments | 47,704 | (15,756) | 46,838 | ||||||||||||||
| Gain on deconsolidation of subsidiaries | (11,027) | (3,108) | (32,772) | ||||||||||||||
| Interest income | (178,109) | (258,375) | (146,425) | ||||||||||||||
| Other (income) expense, net | (4,012) | 10,721 | 13,562 | ||||||||||||||
| Income tax expense | 133,329 | 48,174 | 21,503 | ||||||||||||||
| (Income) loss from discontinued operations, net of tax | — | (373,030) | 315,147 | ||||||||||||||
| Net (loss) income | $ | (397,907) | $ | (356,734) | $ | 4,231,206 | |||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2026 | May 20, 2026 | Showing above |
| 2025 | May 29, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.